 Strategy A: FOLFOX-4 followed, after progression, by irinotecancetuximab Strategy B: irinotecancetuximab followed, after progression, by FOLFOX-4 Patients will be randomly assigned to one of the two treatment sequences with 1:1 ratio using a block design randomization procedure stratified according to center. 